Emma Murphy
Assay Development and Screening Team Leader
Emma received her PhD in Biochemistry from the University of Leicester where she studied the function and mechanism of heme peroxidases and the engineered introduction of novel catalytic activities. Emma continued working on biophysical characterisation of peroxidases as a postdoctoral researcher at University College London before moving to the University of Colorado. Here Emma used a combination of high-throughput in silico and medium-throughput biophysical screening to discover novel compounds that bind to and disrupt the normal functioning of mosquito odorant binding proteins. Emma joined the ODDI in 2015 as an assay development and screening scientist and since 2018 Emma has led the assay development and screening team who develop and run biochemical and biophysical high-throughput screening assays. The team aims to identify chemical matter as tool compounds to validate novel neurodegeneration targets and as potential leads for therapeutic intervention.
Recent publications
-
Regulation of inositol 5-phosphatase activity by the C2 domain of SHIP1 and SHIP2
Preprint
Bradshaw WJ. et al, (2023)
-
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides
Preprint
O’Brien DP. et al, (2022)
-
Aedes aegypti Odorant Binding Protein 22 selectively binds fatty acids through a conformational change in its C-terminal tail
Journal article
Wang J. et al, (2020), Scientific Reports, 10
-
USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation
Journal article
Rusilowicz-Jones EV. et al, (2020), Life Science Alliance, 3, e202000768 - e202000768
-
A novel USP30 inhibitor recapitulates genetic loss of USP30 and sets the trigger for PINK1-PARKIN amplification of mitochondrial ubiquitylation
Preprint
Rusilowicz-Jones E. et al, (2020)